{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T12:39:05Z","timestamp":1789821545437,"version":"4.0.1"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/about_us\/legal\/notices"}],"funder":[{"DOI":"10.13039\/501100003323","name":"ANRS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]},{"name":"French National Agency for Research on AIDS and viral hepatitis"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8,1]]},"DOI":"10.1093\/jac\/dky181","type":"journal-article","created":{"date-parts":[[2018,4,23]],"date-time":"2018-04-23T06:39:50Z","timestamp":1524465590000},"page":"2129-2136","source":"Crossref","is-referenced-by-count":5,"title":["Low-dose ritonavir-boosted darunavir in virologically suppressed HIV-1-infected adults: an open-label trial (ANRS 165 Darulight)"],"prefix":"10.1093","volume":"73","author":[{"given":"Jean-Michel","family":"Molina","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Saint-Louis Hospital, AP-HP, Paris, France"},{"name":"University of Paris Diderot, Sorbonne Paris University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Gallien","sequence":"additional","affiliation":[{"name":"Department of Immunology and Infectious Diseases, Henri-Mondor Hospital, Creteil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Laure","family":"Chaix","sequence":"additional","affiliation":[{"name":"Laboratory of Virology, Saint-Louis Hospital, AP-HP, Paris, France"},{"name":"University of Paris Diderot, Sorbonne Paris University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El Mountacer","family":"El Abbassi","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Saint-Louis Hospital, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Madelaine","sequence":"additional","affiliation":[{"name":"Pharmacy, Saint-Louis Hospital, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Katlama","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Piti\u00e9 Salp\u00eatri\u00e8re Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Valin","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Saint-Antoine Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Delobel","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Toulouse University Hospital, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristell","family":"Desseaux","sequence":"additional","affiliation":[{"name":"University of Paris Diderot, Sorbonne Paris University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Peytavin","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Bichat Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Saillard","sequence":"additional","affiliation":[{"name":"ANRS, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Raffi","sequence":"additional","affiliation":[{"name":"Infectious Disease Department and INSERM CIC 1413, University Hospital of Nantes, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Chevret","sequence":"additional","affiliation":[{"name":"University of Paris Diderot, Sorbonne Paris University, Paris, France"},{"name":"Department of Biostatistics, Saint-Louis Hospital, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ANRS 165 Darulight Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Ponscarme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Lascoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P M","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Rami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Yazdanpanah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Tubiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Duvivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Jeantils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Loreillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Poizot-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Gras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Allavena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Bernaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Bouchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Reliquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Raffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"De Truchis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Charreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Bocquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Lemoing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Point","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J M","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Chevret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E M","family":"El Abbassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Gallien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Tattevin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Gras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M L","family":"Chaix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Peytavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Saillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Couffin-Cadiergues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Madelaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Diallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Gibowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,6,1]]},"reference":[{"key":"key\n\t\t\t\t20180720035944_dky181-B1","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1016\/S2352-3018(16)30087-X","article-title":"Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015","volume":"3","author":"GBD 2015 HIV Collaborators","year":"2016","journal-title":"Lancet HIV"},{"key":"key\n\t\t\t\t20180720035944_dky181-B2","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2165\/00003495-200868050-00001","article-title":"Efficacy and safety of once-daily regimens in the treatment of HIV infection","volume":"68","author":"Molina","year":"2008","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20180720035944_dky181-B3","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1086\/596482","article-title":"Better adherence with once-daily antiretroviral regimens: a meta-analysis","volume":"48","author":"Parienti","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180720035944_dky181-B4","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S2352-3018(17)30179-0","article-title":"Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial","volume":"5","author":"Orkin","year":"2018","journal-title":"Lancet HIV"},{"key":"key\n\t\t\t\t20180720035944_dky181-B5","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","article-title":"Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial","volume":"390","author":"Margolis","year":"2017","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180720035944_dky181-B6","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(17)33095-7","article-title":"Efficacy, safety, and tolerability of dolutegravir\u2013rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies","volume":"391","author":"Llibre","year":"2018","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180720035944_dky181-B7","author":"WHO"},{"key":"key\n\t\t\t\t20180720035944_dky181-B8","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/S0140-6736(13)62187-X","article-title":"Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial","volume":"383","author":"ENCORE1 Study Group","year":"2014","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180720035944_dky181-B9","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S1473-3099(15)70060-5","article-title":"Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study","volume":"15","author":"ENCORE1 Study Group","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20180720035944_dky181-B10","volume-title":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents","author":"DHHS","year":"2017"},{"key":"key\n\t\t\t\t20180720035944_dky181-B11","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/135965350501000213","article-title":"Pharmacokinetics of reduced-dose indinavir\/ritonavir 400\/100 mg twice daily in HIV-1-infected Thai patients","volume":"10","author":"Boyd","year":"2005","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20180720035944_dky181-B12","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1177\/135965350501000806","article-title":"Efficacy and safety of indinavir\/ritonavir 400\/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells\/mm3: 96-week outcomes","volume":"10","author":"Mootsikapun","year":"2005","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20180720035944_dky181-B13","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/jac\/dki143","article-title":"Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability","volume":"55","author":"Cressey","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180720035944_dky181-B14","doi-asserted-by":"crossref","first-page":"e343","DOI":"10.1016\/S2352-3018(16)30010-8","article-title":"LASA Study Group. Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial","volume":"3","author":"Bunupuradah","year":"2016","journal-title":"Lancet HIV"},{"key":"key\n\t\t\t\t20180720035944_dky181-B15","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/jac\/dku390","article-title":"Efficacy of a reduced dose of darunavir\/ritonavir in a cohort of antiretroviral-naive and -experienced HIV-infected patients: a medium-term follow-up","volume":"70","author":"Lanzafame","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180720035944_dky181-B16","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1093\/jac\/dku516","article-title":"DRV600 Study Group. Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial","volume":"70","author":"Molt\u00f3","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180720035944_dky181-B17","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/QAD.0b013e32830285fb","article-title":"Efficacy and safety of once-daily darunavir\/ritonavir versus lopinavir\/ritonavir in treatment-na\u00efve HIV-1-infected patients at week 48","volume":"22","author":"Ortiz","year":"2008","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180720035944_dky181-B18","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1097\/QAD.0b013e32832d7350","article-title":"Once-daily darunavir\/ritonavir vs. lopinavir\/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis","volume":"23","author":"Mills","year":"2009","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180720035944_dky181-B19","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/QAD.0b013e328345ee95","article-title":"Week 48 analysis of once-daily vs. twice-daily darunavir\/ritonavir in treatment-experienced HIV-1-infected patients","volume":"25","author":"Cahn","year":"2011","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180720035944_dky181-B20","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/QAI.0b013e318183a959","article-title":"Efficacy of once-daily darunavir\/ritonavir 800\/100 mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir","volume":"49","author":"De Meyer","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180720035944_dky181-B21","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/M14-1084","article-title":"Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial","volume":"161","author":"Lennox","year":"2014","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20180720035944_dky181-B22","author":"ANRS - AC11: Resistance Study Group"},{"key":"key\n\t\t\t\t20180720035944_dky181-B23","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1177\/0091270006298603","article-title":"The effect of different meal types on the pharmacokinetics of darunavir (TMC114)\/ritonavir in HIV-negative healthy volunteers","volume":"47","author":"Sekar","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180720035944_dky181-B24","author":"ANRS - AC11: Resistance Study Group"},{"key":"key\n\t\t\t\t20180720035944_dky181-B25"},{"key":"key\n\t\t\t\t20180720035944_dky181-B26","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/QAI.0b013e3181989a74","article-title":"Study of the gastrointestinal tolerance of a new tablet formulation of the lopinavir\/ritonavir antiretroviral in HIV-infected patients","volume":"50","author":"S\u00e1ez de la Fuente","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180720035944_dky181-B27","author":"Le"},{"key":"key\n\t\t\t\t20180720035944_dky181-B28","doi-asserted-by":"crossref","first-page":"F11","DOI":"10.1097\/QAD.0b013e3280b07b47","article-title":"Week 24 efficacy and safety of TMC114\/ritonavir in treatment-experienced HIV patients","volume":"21","author":"Haubrich","year":"2007","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180720035944_dky181-B29","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/QAD.0b013e328013d9d7","article-title":"Efficacy and safety of TMC114\/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1","volume":"21","author":"Katlama","year":"2007","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180720035944_dky181-B30","author":"Sekar"},{"key":"key\n\t\t\t\t20180720035944_dky181-B31","doi-asserted-by":"crossref","DOI":"10.1186\/1758-2652-13-S4-P185","article-title":"Pharmacokinetic and pharmacodynamic analyses of once- and twice-daily darunavir\/ritonavir in the ODIN trial","volume":"13","author":"Sekar","year":"2010","journal-title":"J Int AIDS Soc"},{"key":"key\n\t\t\t\t20180720035944_dky181-B32","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/QAD.0b013e3283348944","article-title":"The MONET trial: darunavir\/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies\/mL","volume":"24","author":"Arribas","year":"2010","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180720035944_dky181-B33","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1097\/QAD.0b013e32833dec20","article-title":"Efficacy of darunavir\/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136","volume":"24","author":"Katlama","year":"2010","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180720035944_dky181-B34","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/QAD.0000000000000087","article-title":"Simplification to rilpivirine\/emtricitabine\/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants","volume":"28","author":"Palella","year":"2014","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180720035944_dky181-B35","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1473-3099(14)70782-0","article-title":"Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial","volume":"14","author":"Arribas","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20180720035944_dky181-B36","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/jcph.290","article-title":"Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers","volume":"54","author":"Kakuda","year":"2014","journal-title":"J Clin Pharmacol"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/73\/8\/2129\/25178842\/dky181.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T17:40:38Z","timestamp":1661017238000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/73\/8\/2129\/5026319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,1]]},"references-count":36,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,6,1]]},"published-print":{"date-parts":[[2018,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dky181","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,8]]},"published":{"date-parts":[[2018,6,1]]}}}